Expert perspectives on life sciences strategy, commercialization, and market dynamics.
Expert perspectives on life sciences strategy, commercialization, and market dynamics.
The oncology landscape is expanding at an unprecedented pace and major breakthroughs are creating more possibilities. But quality innovation alone is no longer enough to guarantee commercial success, and the oncology pipeline is crowded. Manufacturers must solidify their strategic positioning early in order to win market share. Driver of pipeline congestion include: Newly druggable targets: […]
Planning a new product launch can be challenging. From assessing market needs to aligning cross-functional teams, companies must follow proven strategies to ensure a smooth, successful launch that meets commercial and compliance expectations.
The shift in the cell and gene therapy capital market may not be shocking to those who have been watching since the post-COVID zeitgeist, when market entry of several clinical successes finally came after decades of innovation and development in the field. Slow clinical progress of many cell and gene therapy programs, coupled with a […]
Challenging post-launch market access is one of the biggest contributors to missed forecasts in recent pharmaceutical launches. Manufacturers launching new therapies are grappling with a variety of strategic choices under the market access umbrella. They’re dealing with optimization of initial coverage, rebate strategy, and affordability programs to mitigate patient out-of-pocket costs. They are also contending […]
As manufacturers seek to capitalize on blockbuster biologic LOEs in the coming years, the adalimumab market has proven that a successful biosimilar launch is not guaranteed. Biosimilars began entering the market about 18 months ago. Despite early access being achieved by leading competitors, Humira’s position in the market and likely portfolio-level rebating were able to […]